文献速递肾血管病与高血压慢性肾脏病

伴或不伴慢性肾脏病患者肾去交感神经术:全球SYMPLICITY注册3年随访结果

Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

本研究基于全球SYMPLICITY注册,比较伴(n=475,eGFR<60)或不伴(n=1505,eGFR≥60)慢性肾脏病的高血压患者接受肾去交感神经术(RDN)后的短期与长期降压效果。结果显示两组诊室及24小时动态血压均较基线显著下降;校正基线后,不伴CKD组36个月诊室收缩压降幅更大,但24小时动态血压降幅相似,且安全性无差异。

要点

  • RDN在伴或不伴CKD的高血压患者中均显著降低诊室及24小时动态血压。
  • 校正基线后,不伴CKD患者36个月诊室收缩压降幅大于伴CKD患者。
  • 两组24小时动态血压降幅及安全性无显著差异。

核心结论

  • 校正基线后,伴与不伴CKD患者RDN后24小时动态收缩压和舒张压降幅相似,但伴CKD患者诊室收缩压降幅较小。
  • RDN是CKD高血压患者的有效降压治疗选择。

研究设计与样本

  • 基于全球SYMPLICITY注册的回顾性比较分析,伴CKD组n=475(eGFR<60 mL/min/1.73 m2),不伴CKD组n=1505(eGFR≥60 mL/min/1.73 m2)。
  • 在预设时间点评估诊室血压和24小时动态血压,随访3年。

主要发现

  • 两组RDN后各时间点诊室血压和24小时动态血压均较基线显著降低(均P<0.001)。
  • 伴CKD患者年龄更大(P<0.001)且使用的降压药更多(P<0.001)。
  • 第一年后两组eGFR年下降率无显著差异。
  • 校正基线后,36个月时不伴CKD组诊室收缩压降幅大于伴CKD组(-17.3 ± 28.3 vs -11.7 ± 29.9 mmHg;P=0.009),舒张压无差异。
  • 两组RDN操作安全性无差异。

关键数值与推荐

  • CKD定义:eGFR<60 mL/min/1.73 m2。
  • 36个月诊室收缩压降幅:不伴CKD组-17.3 ± 28.3 mmHg,伴CKD组-11.7 ± 29.9 mmHg(P=0.009)。

临床怎么用

  • 对于合并CKD的高血压患者,RDN可作为有效的降压治疗选择。
  • 术后需关注诊室收缩压降幅可能小于不伴CKD患者,但24小时动态血压改善相似。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Activity of the sympathetic nervous system is increased in patients with hypertension and chronic kidney disease (CKD). Here we compare short- and long-term blood pressure (BP)-lowering effects of renal denervation (RDN) between hypertensive patients with or without CKD in the Global SYMPLICITY Registry. METHODS: Office and 24-h ambulatory BP (ABP) were assessed at prespecified time points after RDN. The presence of CKD was defined according to the estimated glomerular filtration rate (eGFR) and enrolled patients were stratified based on the presence (n = 475, eGFR <60 mL/min/1.73 m2) or absence (n = 1505, eGFR ≥60mL/min/1.73 m2) of CKD. RESULTS: Patients with CKD were older (P < 0.001) and were prescribed more antihypertensive medications (P < 0.001). eGFR decline per year was not significantly different between groups after the first year. Office and 24-h ABP were significantly reduced from baseline at all time points after RDN in both groups (all P < 0.001). After adjusting for baseline data, patients without CKD had a greater reduction in office systolic BP (-17.3 ± 28.3 versus -11.7 ± 29.9 mmHg; P = 0.009) but not diastolic BP at 36 months compared with those with CKD. Similar BP and eGFR results were found when the analysis was limited to patients with both baseline and 36-month BP data available. There was no difference in the safety profile of the RDN procedure between groups. CONCLUSIONS: After adjusting for baseline data, 24-h systolic and diastolic ABP reduction were similar in patients with and without CKD after RDN, whereas office systolic but not diastolic BP was reduced less in patients with CKD. We conclude that RDN is an effective antihypertensive treatment option in CKD patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ott C, Mahfoud F, Mancia G, et al. Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years. Nephrol Dial Transplant. 2022. PMID: 34109413. doi:10.1093/ndt/gfab154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。